Skip to main
  2. Stocks
  3. Conatus Pharma
CNAT

Buy Conatus Pharma (CNAT) Stock

See CNAT stock price and Buy/Sell Conatus Pharma. Discuss news and analysts' price predictions with the investor community.
Start investing
CNAT

Conatus Pharma (CNAT)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

Invest in CNAT

Order type
Invest in
Amount
Market price$0.00
Estimated quantity0.00
Sign up to buy

About Conatus Pharma (CNAT)

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active ...read more
Market cap
$3.16M
Today's volume
—
Revenue (TTM)
$19K
Avg. daily volume
245.46K
EBITDA (TTM)
-$11.88M
Open
—
Price / earnings ratio
-0.18x
Today's range
—
Debt / equity
—
52 week range
$0.36 - $1.64
Beta (LTM)
0.03x
Dividend & yield
$0.00 (0.00%)
–
Next earnings—

Conatus Pharma Stock Rating

What analysts recommend for CNAT stock, on a scale from 1(buy) to 5(sell).
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Conatus Pharma Stock News

View all
Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists
Newsfile Corp •

Frequently Asked Questions (FAQ)

As of Nov 27, 2023, the market cap for CNAT stock is $3.17M

The current P/E ratio for CNAT stock is -0.18

The 52-week high for CNAT stock is $1.64. The current CNAT stock price $0 is 100.00% below its 52-week high

The 52-week low for CNAT stock is $0.36. The current CNAT stock price $0 has increased 100.00% from its 52-week low

No, the CNAT stock does not pay dividends to its shareholders

The target price for CNAT stock is $2 based on the average of what a group of analyst think CNAT stock could be worth at a future date. This is not a prediction by Public.com

How to buy CNAT stock on Public

1

Sign up for a brokerage account on Public

It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

2

Add funds to your Public account

There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

3

Choose how much you'd like to invest in CNAT stock

Navigate to the Explore page. Then, type CNAT into the search bar. When you see CNAT stock appear in the results, tap it to open up the purchase screen.

4

Manage your investments in one place

You can find your newly purchased CNAT stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Conatus Pharma Stock Earnings

The value each CNAT share was expected to gain vs. the value that each CNAT share actually gained.

Conatus Pharma (CNAT) reported Q3 2023 earnings per share (EPS) of -$0.90, missing estimates of -$0.54 by 66.94%. In the same quarter last year, Conatus Pharma's earnings per share (EPS) was -$1.01. Conatus Pharma is expected to release next earnings on -, with an earnings per share (EPS) estimate of $0.

Buy Conatus Pharma (CNAT) Stock

See CNAT stock price and Buy/Sell Conatus Pharma. Discuss news and analysts' price predictions with the investor community.
Start investing

Invest in CNAT

Order type
Invest in
Amount
Market price$0.00
Estimated quantity0.00
Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Products
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.
Open to the Public Investing, Inc. Customer Relationship Summary

© Copyright 2023 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Product offerings and availability vary based on jurisdiction.

Stocks and ETFs.
Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Additional information can be found here.

Alternative Assets.
Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). This content is not investment advice. These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification by the SEC or as stated in the offering materials relating to an investment opportunity, as applicable. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Crypto.
Cryptocurrency execution and custody services are provided by Bakkt Crypto Solutions LLC (NMLS ID 1828849) through a software licensing agreement between Bakkt Crypto Solutions LLC and Public Platform LLC. Bakkt Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Bakkt Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Bakkt Crypto Disclosures.

Treasuries.
U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“).

JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). T-bills are purchased at a discount to the par value and the T-bill’s yield represents the difference in price between the “par value” and the “discount price.” Aggregate funds in your Treasury Account in excess of the T-bill purchases will remain in your Treasury Account as cash. The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability - yield is subject to change. Past performance is not indicative of future performance. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details.

Investments in T-bills: Not FDIC Insured; No Bank Guarantee; May Lose Value.

Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC.

JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically during the Regular Trading Hours. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more.

View Full Disclosures